Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells

Bioorg Chem. 2022 Mar:120:105576. doi: 10.1016/j.bioorg.2021.105576. Epub 2021 Dec 29.

Abstract

Objective: Caffeine has been studied as a potentiating agent in chemotherapy against some types of cancer, but there are few reports on its effects on melanoma. This study aimed to investigate caffeine's ability to enhance the effects of dacarbazine in vitro.

Materials and methods: Murine melanoma B16F10 cells were treated 24 h with 1-40 µM caffeine. We evaluated cytotoxicity, DNA damage, apoptosis, and oxidative lesion induced by dacarbazine associated with caffeine. The metabolization of these drugs, as well as immunocytochemical labeling, were also evaluated.

Conclusions: The pre-treatment with caffeine showed to be more effective. Caffeine potentiated dacarbazine-induced cytotoxic effects by increasing dacarbazine biotransformation, apoptosis, DNA damage, and malondialdehyde levels; also, caffeine reduced Ki67 and ERK1/2 nuclear labeling and increased p53 labeling in B16F10 cells. In our experiment, caffeine promoted modifications associated with dacarbazine metabolism by viable cells potentiating this antineoplastic drug. These promising results should be further evaluated in experimental models in vivo.

Keywords: B16F10; Caffeine; Cytotoxic; Dacarbazine; Melanoma; Tumor cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Caffeine / pharmacology
  • Cell Line, Tumor
  • Dacarbazine / pharmacology
  • Dacarbazine / therapeutic use
  • Melanoma* / drug therapy
  • Mice

Substances

  • Antineoplastic Agents
  • Caffeine
  • Dacarbazine